Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2b data. The latest results ...
Results from the PATHFINDER 2 trial of Grail's blood test for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology. The Galleri ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback